The Food and Drug Administration released its most recent list of drugs that consumers and health professionals should keep their eye on due to serious risks or new safety information.
One of the drugs on this quarterly list includes Nexavar (Sorafenib tosylate). This drug is used to treat advanced renal cell carcinoma, which is a type of cancer that starts in the kidneys and unresectable hepatocellular carcinoma, which is a type of liver cancer, according to the National Center for Biotechnology Information.
Nexavar is on the watch list because it is linked to osteonecrosis of the jaw or deterioration of the jaw bone. The FDA is evaluating this issue to determine if regulatory action is necessary.
The FDA used the information from the Adverse Event Reporting System (AERS) database from October to December 2011 to identify the new hazards and safety data for the drugs. An appearance of a medication on the list is an indication that there is a potential safety issue, but does not mean there is a cause and effect relationship between the drug and risk.